Acorda shares crater after appeals court dashes remaining hopes for salvaging Ampyra patents — generics loom
Shares of Acorda Therapeutics $ACOR tanked mid-day Monday after the biotech put out the word that a federal appeals court voted 2-to-1 to uphold an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
